Johnson Investment Counsel’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$747K Sell
8,257
-147
-2% -$12.3K 0.01% 518
2026
Q1
$673K Hold
8,404
0.01% 515
2025
Q4
$716K Sell
8,404
-425
-5% -$34.9K 0.01% 470
2025
Q3
$687K Sell
8,829
-200
-2% -$15.6K 0.01% 503
2025
Q2
$706K Buy
9,029
+734
+9% +$54.7K 0.01% 478
2025
Q1
$601K Sell
8,295
-200
-2% -$14.3K 0.01% 493
2024
Q4
$629K Sell
8,495
-616
-7% -$43.1K 0.01% 480
2024
Q3
$601K Buy
9,111
+16
+0.2% +$1.16K 0.01% 483
2024
Q2
$840K Sell
9,095
-75
-0.8% -$6.64K 0.01% 403
2024
Q1
$876K Buy
9,170
+288
+3% +$24.2K 0.01% 398
2023
Q4
$677K Hold
8,882
0.01% 424
2023
Q3
$615K Sell
8,882
-1,095
-11% -$88K 0.01% 423
2023
Q2
$941K Buy
9,977
+1,345
+16% +$117K 0.01% 362
2023
Q1
$714K Sell
8,632
-22
-0.3% -$1.73K 0.01% 398
2022
Q4
$646K Sell
8,654
-250
-3% -$19.3K 0.01% 411
2022
Q3
$736K Buy
8,904
+189
+2% +$18.2K 0.01% 375
2022
Q2
$829K Buy
8,715
+61
+0.7% +$6.32K 0.01% 361
2022
Q1
$1.02M Sell
8,654
-53
-0.6% -$5.95K 0.01% 346
2021
Q4
$1.13M Hold
8,707
0.01% 332
2021
Q3
$986K Buy
8,707
+5
+0.1% +$571 0.01% 347
2021
Q2
$901K Sell
8,702
-187
-2% -$17.6K 0.01% 348
2021
Q1
$743K Sell
8,889
-25
-0.3% -$2.11K 0.01% 364
2020
Q4
$813K Sell
8,914
-167
-2% -$13.9K 0.01% 338
2020
Q3
$725K Hold
9,081
0.01% 334
2020
Q2
$628K Sell
9,081
-453
-5% -$32.2K 0.01% 356
2020
Q1
$599K Sell
9,534
-654
-6% -$47.2K 0.01% 332
2019
Q4
$792K Buy
10,188
+45
+0.4% +$3.51K 0.01% 353
2019
Q3
$744K Buy
10,143
+894
+10% +$62.8K 0.01% 353
2019
Q2
$569K Hold
9,249
0.01% 401
2019
Q1
$589K Buy
9,249
+24
+0.3% +$1.37K 0.01% 386
2018
Q4
$470K Sell
9,225
-660
-7% -$33.4K 0.01% 408
2018
Q3
$573K Buy
9,885
+558
+6% +$27.3K 0.01% 412
2018
Q2
$452K Sell
9,327
-894
-9% -$41.7K 0.01% 445
2018
Q1
$475K Sell
10,221
-732
-7% -$31.8K 0.01% 430
2017
Q4
$411K Sell
10,953
-7,845
-42% -$288K 0.01% 469
2017
Q3
$684K Buy
18,798
+810
+5% +$30.9K 0.02% 339
2017
Q2
$708K Buy
17,988
+537
+3% +$19.6K 0.02% 317
2017
Q1
$547K Sell
17,451
-180
-1% -$5.64K 0.02% 376
2016
Q4
$550K Sell
17,631
-2,349
-12% -$76.1K 0.02% 348
2016
Q3
$802K Sell
19,980
-216
-1% -$8.13K 0.03% 259
2016
Q2
$671K Hold
20,196
0.02% 281
2016
Q1
$593K Buy
20,196
+516
+3% +$14.2K 0.02% 292
2015
Q4
$518K Sell
19,680
-1,920
-9% -$49.9K 0.02% 318
2015
Q3
$511K Hold
21,600
0.02% 317
2015
Q2
$512K Hold
21,600
0.02% 316
2015
Q1
$512K Sell
21,600
-102
-0.5% -$2.29K 0.02% 317
2014
Q4
$460K Hold
21,702
0.02% 337
2014
Q3
$369K Buy
+21,702
New +$343K 0.01% 391

Other funds holding EW

Johnson Investment Counsel's EW Position: Q2 2026 in Review

Johnson Investment Counsel reduced its Edwards Lifesciences (EW) stake by 1.7% in Q2 2026, selling an estimated $12.3K and leaving 8,257 shares worth $747K. The position accounts for 0.01% of the portfolio, ranked #518.

Johnson Investment Counsel first reported a position in EW in Q3 2014 and has held it in 48 quarters since. The position peaked at $1.13M in Q4 2021. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Johnson Investment Counsel held 8,257 shares of Edwards Lifesciences worth $747K as of Q2 2026.
  • Johnson Investment Counsel sold 147 Edwards Lifesciences shares in Q2 2026, an estimated $12.3K.
  • Edwards Lifesciences made up 0.01% of Johnson Investment Counsel's portfolio in Q2 2026, its #518 holding.
  • Johnson Investment Counsel first reported a position in Edwards Lifesciences in Q3 2014 and has held it in 48 quarters since.
  • Johnson Investment Counsel's Edwards Lifesciences position peaked at $1.13M in Q4 2021.
  • 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Johnson Investment Counsel's 13F filing for Q2 2026, filed 23 Jul 2026.